Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs (Q37998132)

26 August 2017

title

Progress in the development of anti-hepatitis C virus nucleoside and nucleotide prodrugs (English)

1 reference

26 August 2017

1 reference

Karolina Madela

1

1 reference

26 August 2017

Christopher McGuigan

series ordinal

2

1 reference

26 August 2017

publication date

1 April 2012

1 reference

Future Medicinal Chemistry

26 August 2017

published in

1 reference

26 August 2017

volume

4

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

625-650

1 reference

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

26 August 2017

cites work

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence

21 January 2018

1 reference

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

21 January 2018

1 reference

The origin of hepatitis C virus genotypes.

21 January 2018

1 reference

Expert opinion on the treatment of patients with chronic hepatitis C

21 January 2018

1 reference

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Protease and polymerase inhibitors for the treatment of hepatitis C.

21 January 2018

1 reference

Genetic diversity and evolution of hepatitis C virus--15 years on

21 January 2018

1 reference

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

21 January 2018

1 reference

Multiple interactions within the hepatitis C virus RNA polymerase repress primer-dependent RNA synthesis

21 January 2018

1 reference

Further Insights into the Roles of GTP and the C Terminus of the Hepatitis C Virus Polymerase in the Initiation of RNA Synthesis

21 January 2018

1 reference

Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends

21 January 2018

1 reference

Identification of allosteric inhibitors blocking the hepatitis C virus polymerase NS5B in the RNA synthesis initiation step

21 January 2018

1 reference

Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides.

21 January 2018

1 reference

Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase

21 January 2018

1 reference

Emerging host cell targets for hepatitis C therapy

21 January 2018

1 reference

HCV antiviral resistance: the impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase

21 January 2018

1 reference

Canonical 3'-deoxyribonucleotides as a chain terminator for HCV NS5B RNA-dependent RNA polymerase

21 January 2018

1 reference

Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets

21 January 2018

1 reference

The design of drugs for HIV and HCV

21 January 2018

1 reference

Nucleotide prodrugs for HCV therapy

21 January 2018

1 reference

Advances in nucleoside monophosphate prodrugs as anti-HCV agents

21 January 2018

1 reference

Nucleoside analog inhibitors of hepatitis C virus replication

21 January 2018

1 reference

Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.

21 January 2018

1 reference

In vitro selected Con1 subgenomic replicons resistant to 2'-C-methyl-cytidine or to R1479 show lack of cross resistance

21 January 2018

1 reference

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

21 January 2018

1 reference

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors

21 January 2018

1 reference

Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.

21 January 2018

1 reference

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.

21 January 2018

1 reference

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

21 January 2018

1 reference

Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication

21 January 2018

1 reference

Mechanism of Activation of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine and Inhibition of Hepatitis C Virus NS5B RNA Polymerase

21 January 2018

1 reference

Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species

21 January 2018

1 reference

Prodrugs of phosphates and phosphonates

21 January 2018

1 reference

Nucleoside analogues: mechanisms of drug resistance and reversal strategies.

21 January 2018

1 reference

Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells

21 January 2018

1 reference

Lipophilic phosphoramidates as antiviral pronucleotides

21 January 2018

1 reference

Prodrug approaches of nucleotides and oligonucleotides

21 January 2018

1 reference

Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT

21 January 2018

1 reference

Synthesis and anti-HIV activity of some haloalkyl phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT): potent activity of the trichloroethyl methoxyalaninyl compound

21 January 2018

1 reference

Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus.

21 January 2018

1 reference

Application of the phosphoramidate ProTide approach to 4'-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside.

21 January 2018

1 reference

First example of phosphoramidate approach applied to a 4'-substituted purine nucleoside (4'-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus

21 January 2018

1 reference

Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite.

21 January 2018

1 reference

Mechanism of anti-HIV action of masked alaninyl d4T-MP derivatives

21 January 2018

1 reference

Synthesis and evaluation of novel amidate prodrugs of PMEA and PMPA.

21 January 2018

1 reference

Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency

21 January 2018

1 reference

Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives

21 January 2018

1 reference

Phosphate prodrugs derived from N-acetylglucosamine have enhanced chondroprotective activity in explant cultures and represent a new lead in antiosteoarthritis drug discovery

21 January 2018

1 reference

Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T).

21 January 2018

1 reference

Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-beta-arabinofuranosylcytosine: evidence of phosphoramidase activity

21 January 2018

1 reference

Direct measurement of nucleoside monophosphate delivery from a phosphoramidate pronucleotide by stable isotope labeling and LC-ESI(-)-MS/MS.

21 January 2018

1 reference

Synthesis, in vitro anti-breast cancer activity, and intracellular decomposition of amino acid methyl ester and alkyl amide phosphoramidate monoesters of 3'-azido-3'-deoxythymidine (AZT).

21 January 2018

1 reference

Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: intracellular delivery of 3'-azido-2',3'-dideoxythymidine 5'-monophosphate

21 January 2018

1 reference

Decomposition pathways and in vitro HIV inhibitory effects of isoddA pronucleotides: toward a rational approach for intracellular delivery of nucleoside 5'-monophosphates

21 January 2018

1 reference

Synthesis and biological activity of 7-deaza-7-ethynyl-2'-deoxy-2'-fluoro-2'-C-methyladenosine and its 2'-C-methyl-ribo analogue

21 January 2018

1 reference

2'-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replication

21 January 2018

1 reference

Cyclic monophosphate prodrugs of base-modified 2'-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication

21 January 2018

1 reference

Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects

21 January 2018

1 reference

Synthesis and properties of some cyclic AMP alkyl phosphotriesters

21 January 2018

1 reference

2'-O-Acyl-6-thioinosine cyclic 3',5'-phosphates as prodrugs of thioinosinic acid

21 January 2018

1 reference

Synthesis, structure, and reactivity of adenosine cyclic 3',5'-phosphate-benzyltriesters

21 January 2018

1 reference

2′-Deoxy-2′-α-fluoro-2′-β-C-methyl 3′,5′-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: Discovery of PSI-352938

21 January 2018

1 reference

Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine

21 January 2018

1 reference

Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver

21 January 2018

1 reference

Liver-targeted drug delivery using HepDirect prodrugs

21 January 2018

1 reference

Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection

21 January 2018

1 reference

Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees

21 January 2018

1 reference

The Mechanism of Action of -D-2'-Deoxy-2'-Fluoro-2'-C-Methylcytidine Involves a Second Metabolic Pathway Leading to -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine 5'-Triphosphate, a Potent Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase

21 January 2018

1 reference

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

21 January 2018

1 reference

Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977

21 January 2018

1 reference

The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4'-azidocytidine (R1479).

21 January 2018

1 reference

Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs

21 January 2018

1 reference

The phosphoramidate ProTide approach greatly enhances the activity of beta-2'-C-methylguanosine against hepatitis C virus.

21 January 2018

1 reference

Liver-targeted prodrugs of 2'-C-methyladenosine for therapy of hepatitis C virus infection

21 January 2018

1 reference

Robust Antiviral Efficacy upon Administration of a Nucleoside Analog to Hepatitis C Virus-Infected Chimpanzees

21 January 2018

1 reference

Phosphoramidate ProTides of 2'-C-methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and in vivo properties.

21 January 2018

1 reference

Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus.

21 January 2018

1 reference

Dual pro-drugs of 2'-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus.

21 January 2018

1 reference

INX-08189, a phosphoramidate prodrug of 6-O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties.

21 January 2018

1 reference

Discovery of PSI-353661, a Novel Purine Nucleotide Prodrug for the Treatment of HCV Infection

21 January 2018

1 reference

Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661.

21 January 2018

1 reference

6-Hydrazinopurine 2'-methyl ribonucleosides and their 5'-monophosphate prodrugs as potent hepatitis C virus inhibitors

21 January 2018

1 reference

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

21 January 2018

1 reference

Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients

21 January 2018

1 reference

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

21 January 2018

1 reference

Physiological concentrations of purines and pyrimidines

21 January 2018

1 reference

Immunopathogenesis of hepatitis C virus infection

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/FMC.12.10

1 reference

26 August 2017

1 reference